New Leaf Venture Partners, L.L.C. Crinetics Pharmaceuticals, Inc. Transaction History
New Leaf Venture Partners, L.L.C.
- $43.2 Million
- Q3 2025
A detailed history of New Leaf Venture Partners, L.L.C. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, New Leaf Venture Partners, L.L.C. holds 141,000 shares of CRNX stock, worth $6.14 Million. This represents 13.58% of its overall portfolio holdings.
Number of Shares
141,000
Previous 141,000
-0.0%
Holding current value
$6.14 Million
Previous $4.06 Million
44.81%
% of portfolio
13.58%
Previous 12.06%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
93MCall Options Held
1.02MPut Options Held
204K-
Vanguard Group Inc Valley Forge, PA9.17MShares$399 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$365 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$282 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$251 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...